FIGURE 3

ZF in vivo efficacy of CLA-OMD. The drug concentrations that show 1 log₁₀ CFU reduction were determined using different concentrations of CLA, BDQ, AMK, OMD, RFB, and CFX in Mab infected ZF model (A). To determine in vivo efficacy, survival curve was plotted from MabR-mWasabi infected ZF for 13 days (n = 20, representative of three independent experiments) (B). Each different combination treatment was carried out. CLA (3.1 ?M) was combined with BDQ (3.1 ?M), AMK (12.5 ?M), OMD (6.3 ?M), RFB (6.3 ?M), and CFX (6.3 ?M) respectively. Survival curves were constructed using the log-rank (Mantel-Cox) test (**p < 0.01; ***p < 0.001). Inf UNT: Infected but not treated control. Therapeutic outcome using drug combinations was validated by traditional agar plate quantification method (C). Data was expressed as the mean log₁₀ CFU per embryo (n = 10 of each condition) from three independent experiments. Drug combination effect was also observed using fluorescence under microscope. Each drug combinations were treated to the ZF infected with MabR-mWasabi and reduction of mWasabi signal in ZF was monitored under the fluorescent microscope (D).